Last reviewed · How we verify
NCT02859753: Thermoablation
Comparison of Response and Recurrence Rates Following Percutaneous Microwave Coagulation Therapy Versus Percutaneous Radiofrequency Ablation
NA trial testing Percutaneous Radiofrequency Ablation in Thermoablation in 35 participants. Completed in 18 March 2020.
18 March 2020
Quick facts
| Lead sponsor | Centre Hospitalier Universitaire Dijon |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | other |
| Enrollment | 35 |
| Start date | 15 January 2014 |
| Primary completion | 18 March 2020 |
| Estimated completion | 18 March 2020 |
| Sites | 1 location across France |
Drugs / interventions tested
- Percutaneous Radiofrequency Ablation
- Percutaneous Microwave Ablation
Conditions studied
- Thermoablation — all drugs for Thermoablation →
- Chronic Liver Disease — all drugs for Chronic Liver Disease →
- Hepatocellular Carcinoma — all drugs for Hepatocellular Carcinoma →
Sponsor
Centre Hospitalier Universitaire Dijon
Who can join
18 and older, any sex, with Thermoablation or Chronic Liver Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To date, the majority of studies that have evaluated the efficacy of microwave ablation (MWA) in the treatment of hepatocellular carcinoma (HCC) lesions in cirrhotic patients and compared its efficacy with that of percutaneous radiofrequency ablation (RFA) for local recurrence and survival have been retrospective. There have been no prospective randomized studies comparing percutaneous microwave ablation (PMWA) with RFA for ablated tumour volume, the response after one session, local recurrence rates in the first year, complication rates and survival at 3 and 5 years for HCC lesions \> 2 cm in patients with Child-Pugh A and B cirrhosis. The hypothesis the investigators wish to explore is that though the 2 methods are equivalent for lesions ≤ 2 cm, MWA could show better efficacy with a similar risk for lesions \> 2 cm and for lesions close to vessels ≥ 3 mm in diameter, as shown in retrospective studies.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Efficacy of microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma in patients with chronic liver disease: a randomised controlled phase 2 trial.
Vietti Violi N, Duran R, Guiu B, Cercueil JP, et al · · 2018 · cited 196× · PMID 29503247 · DOI 10.1016/s2468-1253(18)30029-3
Verify or expand the search:
- PubMed search for NCT02859753
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Percutaneous Radiofrequency Ablation
Trials testing the same drug.
- NCT05445973 — Added Value of Contrast-enhanced Ultrasonography for Percutaneous Radiofrequency Ablation · NA · completed
Other Centre Hospitalier Universitaire Dijon trials
Trials by the same sponsor.
- NCT06608004 — Influence of Olfacto-gustatory Sensoriality on the Nutritional Status of Patients With Amyotrophic Lateral Sclerosis · recruiting
- NCT07432789 — Metrological Properties of a Digital Motion Analysis Research Application for Assessing the Motor Abilities and Performa · NA · recruiting
- NCT06776848 — A Pilot, Multicentre, Controlled, Open-label Study Evaluating 24 Months of Lithium Carbonate Treatment in Patients With · Phase 1, PHASE2 · recruiting
- NCT06347302 — Study of Vitreoretinal Molecular Changes During Rhegmatogenous Retinal Detachment · NA · completed
- NCT06252415 — Evaluation of Rapid First-line Genome Sequencing for Prenatal Diagnosis of Congenital Malformations in Comparison With C · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02859753 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier Universitaire Dijon
- Last refreshed: 21 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02859753.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing